Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Executive Summary
Pfizer expects at least 30 months of additional exclusivity for the epilepsy agent Neurontin (gabapentin) beyond the expiration of the basic compound patent July 15.